JHOP - June 2019 Vol 9, No 2
Esra Nusseibeh, PharmD, Lynn Weber, PharmD, BCOP, Katie Won, PharmD, BCOP, Shannon Reidt, PharmD, MPH
Shabnam Dakwala-Sheikh, PharmD, Genevieve Moore, PharmD, Leila Mohassel, PharmD, BCPS, BCOP, Casey Washington, PharmD, BCPS
Veronica Ajewole, PharmD, BCOP, Lindsay Edmondson, PharmD, BCOP, Edward McLean, PharmD, BCOP, Kirk Heyne, MD, Lawrence Rice, MD
The European Society for Medical Oncology-European Oncology Nursing Society (ESMO-EONS) defines extravasation as the unintended leakage of a substance into the subcutaneous or subdermal tissue around the intravenous or intra-arterial administration site.
A paradigm shift in the management of relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma (NHL) has evolved in recent years. With increased use of targeted therapies, ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, is an integral therapeutic option for patients with treatment-naïve and treatment-experienced CLL or low-grade NHL. Ibrutinib therapy demonstrated superior overall response rates compared with ofatumumab and other agents in treatment-experienced patients with CLL.
Breast cancer research continues to extend survival across all subsets and settings of the disease, according to Sandra Cuellar, PharmD, BCOP, Director, PGY-2 Oncology and Clinical Oncology Pharmacist and Clinical Assistant Professor, University of Illinois Hospital and Health Sciences System, Chicago.
Pharmacists play an invaluable role on the oncology care team for the management of chemotherapy-induced nausea and vomiting (CINV). But although the pipeline for new cancer drugs expands, the number of novel antiemetics in the pipeline is drying up, underlining the importance of the pharmacist’s knowledge of the available antiemetics for patients undergoing chemotherapy.
Results 1 - 9 of 9